Update on HPV Vaccination
Human papillomavirus is a sexually transmitted virus responsible for cancer of the cervix, vagina, vulva, anus, penis, oral cavity, and oropharynx. Primary prevention of this infection by HPV vaccination can prevent most cases of cervical cancer in women, if given before sexual debut. Though the quadrivalent and bivalent vaccines were approved by the FDA in 2006 and 2009, respectively, the 9-valent vaccine was approved in 2017. This chapter will discuss the newly available nonavalent HPV vaccine (its rationale, efficacy, and cost-effectiveness comparable to older vaccines), changes in dosage schedules, safety updates, and under research therapeutic vaccines.
KeywordsHPV Vaccination Bivalent Quadrivalent Nonavalent vaccine Therapeutic vaccine
- 1.National Advisory Committee on Immunization. Update on human papillomavirus (HPV) vaccines. An advisory committee statement. Commun Dis Rep. 2012;38:1–62.Google Scholar
- 3.World Health Organization. Human papillomavirus vaccines. WHO position paper, May 2017 [PDF]. Wkl Epidemiol Rec 19. 12 May 2017;92:241–68.Google Scholar
- 4.World Health Organization. The immunological basis for immunization series. Module 19: human papillomavirus infection [PDF]. May 2011.Google Scholar
- 11.Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.CrossRefGoogle Scholar
- 24.World Health Organization. Comprehensive cervical cancer prevention and control: a healthier future for girls and women. Geneva: World Health Organization; 2013.Google Scholar
- 25.Global immunization data: WHO 2015. Available from: https://www.who.int/immunization/monitoring_surveillance/en/. Accessed 15 Nov 2015.
- 29.Department of Health and Public Health England. JVCI interim position statement on HPV vaccination of men who had sex with men. 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment-data/fil.
- 35.Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 ASO4-adjuvanted vaccine administered as 2 dose schedule compared to the licensed 3 dose schedule: results from a randomised study. Hum Vaccin. 2011;7:1374–86.CrossRefGoogle Scholar
- 39.World Health Organization. Global advisory committee on vaccine safety statement on the continued safety of HPV vaccination. 12 March 2014. http://www.who.int/vaccine_safety/committee/topic/hpv/GAVC_statement_HPv_12_March_2014.pdf.
- 42.REVEAL 1 (evaluation of VGX-3100 and electroporation for the treatment of cervical HSIL). Clinicaltrials.gov. https://clinicaltrial.gov